| Cancer name | Skin Cutaneous Melanoma |
| Cancer Type | SKCM |
| Immunotherapy type | Immune Checkpoint Therapy |
| Treatment | pembrolizumab |
| Drugstatus | Approved |
| Drugbank ID | DB09037 |
| Checkpoints | PD-1 |
| Signature Type | Protein |
| Signature | Rantes |
| Official Symbol | CCL5 |
| Mode of action | TRAN_NR_DOWN |
| Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals. | |
| Experimental | clinical trail |
| Description | IFNG was among the genes that most significantly influenced the outcome of the melanoma patients treated with pembrolizumab. With a median follow up of 12.4 (95% CI 7.3–18.0) months, median progression-free survival was 1.9 months (95% CI 0.0–5.1) and 5.0 (95% CI 1.5–14.1) months for patients with low and high IFNG mRNA, respectively (p= 0.0099), (HR for dis-ease progression, 3.77; 95% CI 1.23–11.16; p=0.0164). Univariate analy-sis revealed that low IFNG mRNA expression and elevated lactate dehydrogenase (LDH) levels were significantly associated with shorter progres-sion-free survival. Paradoxically, low Rantes mRNA expression was also significantly associated with shorter progression-free survival. However, in the Cox’s regression model, only LDH levels remained a significant predictor of progression-free survival (HR for disease progres-sion, 3.13; 95% CI 1.04–9.42; p= 0.0419; Table 5). There was a trend for IFNG levels to be asso-ciated with progression-free survival (HR for dis-ease progression, 3.29; 95% CI 0.83–13.08; p=0.0910) |
| PMID | 29383037 |
| Title | Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients |